Standout Papers

Endothelial Activation and Blood–Brain Barrier Disr... 2009 2026 2014 2020 913
  1. Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells (2017)
    Juliane Gust, Kevin A. Hay et al. Cancer Discovery
  2. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells (2009)
    Harlan Robins, Paulo Vidal Campregher et al. Blood
  3. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy (2017)
    Kevin A. Hay, Laïla‐Aïcha Hanafi et al. Blood
  4. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells (2016)
    Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. Science Translational Medicine
  5. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015)
    Daniel Sommermeyer, Michael Hudecek et al. Leukemia
  6. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy (2016)
    Rebecca Gardner, David Wu et al. Blood
  7. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes (2020)
    Daniel E. Leisman, Lukas Ronner et al. The Lancet Respiratory Medicine
  8. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib (2017)
    Cameron J. Turtle, Kevin A. Hay et al. Journal of Clinical Oncology
  9. HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells (2017)
    Germán G. Gornalusse, Roli K. Hirata et al. Nature Biotechnology
  10. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy (2017)
    Joshua A. Hill, Daniel Li et al. Blood
  11. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure (2020)
    Jordan Gauthier, Alexandre V. Hirayama et al. Blood
  12. Immunogenicity of CAR T cells in cancer therapy (2021)
    Dimitrios L. Wagner, Enrico Fritsche et al. Nature Reviews Clinical Oncology

Immediate Impact

8 by Nobel laureates 25 from Science/Nature 147 standout
Sub-graph 1 of 14

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
Principles and therapeutic applications of adaptive immunity
2024 Standout
62 intermediate papers

Works of Cameron J. Turtle being referenced

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
2020 Standout
Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
2009 Standout
and 32 more

Author Peers

Author Last Decade Papers Cites
Cameron J. Turtle 8393 3732 2937 162 11.4k
Noelle V. Frey 7415 2651 2193 160 9.3k
David T. Teachey 10348 4836 3671 191 15.1k
Michael Kalos 11484 5916 4825 94 15.2k
Terry J. Fry 8286 6091 2697 188 12.8k
Adrian P. Gee 9430 5186 3108 217 14.2k
Hao Liu 9186 4215 2789 87 11.1k
Shannon L. Maude 7458 2496 2096 107 8.9k
Adam Bagg 6849 3097 3769 212 11.6k
Crystal L. Mackall 6851 8317 3141 167 15.7k
Crystal L. Mackall 9385 4754 3450 146 12.4k

All Works

Loading papers...

Rankless by CCL
2026